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Care of the surgical patient: At a glance 
Part 2: Oral Anticoagulants  
Introduction 
As individuals are living longer with comorbidities and complex healthcare needs, some of the patients 
requiring surgical intervention can present with additional challenges for perioperative staff (Holt, 
2012; Dhatariya, et al., 2016; Keeling, Tait and Watson, 2016). It is imperative that these are addressed 
throughout the perioperative care continuum, in addition to the standard guidelines and care 
requirements for surgical patients (refer to article ‘Care of the Surgical Patient: Part 1, Robertson and 
Ford, 2020), to reduce the risk of further complications. To demonstrate some of these challenges, this 
article provides some supplementary information regarding patients who are prescribed oral 
anticoagulants and are undergoing a surgical procedure.  
Anticoagulation therapy 
Anticoagulant therapy and its role within the treatment of cardiovascular disorders (people with atrial 
fibrillation and mechanical prosthetic heart valves) is well recognised (NICE, 2020a); however, there 
is now an increased awareness and acceptance of its use to treat and prevent against stroke and 
thromboembolism, all of which have implications for patients who are undergoing surgery (Pavord 
and Webster, 2015; Douketis and Lip, 2019). If prescribed anticoagulants are continued during surgery 
• Introduce the readers to some of the additional risks associated with patients who are undergoing 
surgery and taking oral anticoagulants.  
• Explore the use of vitamin K antagonists and heparin 
•  Discuss some of the management strategies and additional considerations that need to be 
addressed during the perioperative care continuum.  
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or invasive procedures the risk of bleeding increases and additional potential harm may occur from the 
use of regional anaesthetics, including epidurals; however, if they are stopped, further 
thromboembolisms may develop (Keeling et al., 2011). Therefore, for patients receiving 
anticoagulation therapy, perioperative management must be holistically tailored depending upon the 
patient’s, current medication, International Normalised Ratio (INR), thromboembolism risk and the 
type of surgery/anaesthetic that the patient is scheduled to receive (Association of Anaesthetists of 
Great Britain and Ireland (AAGBI), 2016; Dubois et al., 2017). With recent developments in 
pharmacology, there is now a range of direct oral anticoagulants (DOAC), such as Apixaban, 
Dabigatran, Edoxaban and Rivaroxaban, which have a fast onset of action; however, for the purpose 
of this article, we will focus on vitamin K antagonists and heparin, as these are the most commonly 
used (McIlmoyle and Tran, 2018).  
Vitamin K Antagonists, as the name would suggest, inhibit several coagulation processes in which 
vitamin K is a co-factor (McIlmoyle and Tran, 2018). Namely, the conversion of glutamine acid to y-
carboxyglutamic acid which is needed for the synthesis of prothrombin (coagulation factor ii), 
proconvertin (coagulation factor vii), plasma thromboplastin component (coagulation factor ix) and 
Stuart-Prower factor (coagulation factor x), and natural anticoagulants protein S and C (see figure 4) 
(Pavord and Webster, 2015). The most commonly used vitamin K antagonist is Warfarin (AAGBI, 
2016). Warfarin is orally bioavailable and rapidly absorbed in the gastrointestinal tract; however, it 
has a varied half-life and causes many pharmacological interactions. These can decrease the 
effectiveness of the warfarin, increasing the risk of clot formation or the risk of bleeding and 
haemorrhage. Therefore, warfarin requires careful and close monitoring especially when administered 
alongside drugs that are known to interact with it, such as, paracetamol, ibuprofen, aspirin-based 
medication and antacids or laxatives (Pavord and Webster, 2015).  
Heparins are sulphated glycosaminoglycans, which are isolated from porcine tissue (Martin and Hine, 
2015). They are used for their ability to inhibit blood coagulation by binding to antithrombin and 
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enhancing its ability to inhibit thrombin production and fibrin clot formation, which are involved in 
the coagulation cascade process (see figure 4) (Pavord and Webster, 2015). The two main types of 
heparin are unfractured heparin (UFH) and low molecular weight heparin (LMWH); however, LMWH 
is usually preferred over (UFH) as LMWH due to its increased bioavailability and potential for reduced 
side effects (McIlmoyle and Tran, 2018; Douketis and Lip, 2019) (see figure 2).  
 
International Normalised Ratio (INR) 
International Normalised Ratio (INR) is a laboratory test used to check the anticoagulant effect of 
warfarin by using the outcome of the prothrombin time (PT) test, a measurement which monitors the 
time it takes blood to coagulate (Anderson, Wool and Madden, 2019). Target INR for those prescribed 
anticoagulants is ideally 2.5 (therapeutic range between 2-3), or 3.5 for individuals with recurrent 
VTE’s (Keeling et al., 2011; Pavord and Webster, 2015; AAGBI, 2016; NICE, 2020). If the patient’s 
INR is 1.5 or above at the time of surgery, the balance of the risk of haemorrhage versus the urgency 
of undertaking the operation must be considered by the surgical team. INR should also be ideally 
measured the day before an operation in patients taking warfarin so that vitamin K can be administered 
if the INR is 1.5 or above, as this reverses warfarin’s effect of inhibiting the synthesis of vitamin K 
dependent clotting factors, reducing the risk of bleeding and the possible need to cancel the surgery 
(Keeling et al., 2011; NICE, 2020). If surgery is required urgently, to reverse warfarin anticoagulation, 
prothrombin complex concentrate can be used (Pavord and Webster, 2015) and to reverse the effects 
of heparin, protamine sulfate can be used to ensure the action of thrombin and fibrin in the coagulation 




Venous Thromboembolism (VTE) is the overarching term used to describe deep vein thrombosis 
(DVT) and pulmonary embolism (PE) and is associated with the formation of a blood clot, known as 
a thrombus, in a vein. Thrombi has the potential to become dislodged, creating an embolism in another 
part of the body (Duff et al., 2013; Rayt and Nasim, 2015). The thrombus usually develops in one of 
the larger and deeper veins of the body (most commonly the deep veins of the pelvis, thigh and lower 
leg). They are more prevalent in individuals whose blood is hypercoagulable and can also be caused 
by venous injury and venous stasis. As the body usually relies on movement and contraction of the 
lower limb muscles to assist with venous return, surgical patients, especially those undergoing a 
general anaesthetic and immobile, are therefore at higher risk of developing a thrombus.  NICE (2018a) 
state that VTE has been attributed as being a major cause of death in hospitalised patients, with 
approximately 6500 annual deaths attributed to VTE in the UK, many of which can be avoidable. 
Consequently, VTE prevention has been recognised as a clinical priority for the NHS and completion 
of a VTE risk assessment is required for all patients admitted to hospital, just after admission or before 
the first consultant review (NICE, 2018a). This also has significance for surgical patients, as deaths 
due to post-operative strokes are substantially higher than fatalities because of bleeding (Keeling et 
al., 2011; NICE, 2020). These risk assessments can be used to help determine and document if a patient 
is at increased risk of developing a thrombus as well as their risk of bleeding, both of which are taken 
into account when making decisions on whether anticoagulants are continued, stopped or if bridging 
therapy is required (Douketis, 2019) (see an example of general VTE risk assessment in figure 1).  
Type of surgery  
Another factor used when making a decision about treatment is also related to the surgery type, the 
surgical site and the individual patient’s anatomy (Keeling, Tait and Watson, 2016). For example, if 
patients are undergoing procedures with a low risk of bleeding including cataract surgery, minor 
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dermatological surgery, a biopsy of a site that can be compressed to stop bleeding and joint 
aspiration/injection, anticoagulants may be continued (Keeling et al., 2011; Dubois et al., 2017).  In 
contrast, for procedures with a high risk of bleeding, such as cardiovascular surgery, thoracic surgery, 
spinal surgery, liver and kidney biopsy, major abdominal surgery, cranial surgery and orthopaedic 
surgery, anticoagulants may need to be stopped (Lai et al., 2014). Keeling, Tate and Watson (2016) 
suggest that while some surgeries can be considered at a lower or higher risk of bleeding, each case 
should be examined individually, and decisions to reduce, stop or replace anticoagulants should be 
made collaboratively between the operating team and patient.  If it is necessary to stop warfarin before 
a procedure, individuals should be instructed to cease medication five days before the surgery, INR 
should be measured on the day before surgery, to allow administration of vitamin K if it is greater than 
or equal to 1.5 and re-checked on the morning of surgery if vitamin K has been administered (AAGBI, 
2016). 
Bridging therapy 
Bridging therapy in the case of anticoagulant therapy refers to a pharmacological bridge that is created 
during a period when warfarin therapy is interrupted and when the INR is not within a therapeutic 
range. Medications that may be used for bridging therapy include UFH and LMWH e.g. tinzaparin 
(AAGBI, 2016). Bridging therapy may be required both preoperatively and postoperatively to balance 
the risk between a thromboembolism forming and major haemorrhage during the surgical intervention 
and patients will need to remain on this bridging therapy until they can resume their usual 
anticoagulant. If the patient has undergone surgery with a high risk of postoperative bleeding, it may 
be necessary to wait at least 48 hours before commencing bridging therapy (Keeling, Tait and Watson, 
2016). However, bridging therapy should not be used routinely, as warfarin should never be interrupted 
for procedures of low bleeding risk or when patients are assessed as being at low risk of 
thromboembolism (Douketis and Lip, 2019). For patients who are at intermediate risk the decision for 
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perioperative use will depend upon the type of surgery and whether there is an increased risk of 
bleeding during or after the surgery and this will be patient-specific (McIlmoyle and Tran, 2018).  For 
high-risk patients, bridging therapy should be considered and warfarin should be stopped 5 days before 
the surgery (see figure 3) (AAGBI, 2016). 
Neuraxial and peripheral nerve blocks 
It is recommended by AAGBI (2013) that for high-risk patients, regional anaesthesia should be utilised 
where possible due to the postoperative benefits of early mobility and the continuation of anticoagulant 
therapy. However, careful consideration must be undertaken with regards to the use, insertion and 
removal of epidurals or spinal anaesthesia/analgesia for patients who are receiving anticoagulant 
therapy, as clinically significant bleeding can cause neurological dysfunction (Horlocker, 2011; 
AAGBI, 2013). During insertion, coagulation status (INR) must be within therapeutic range and 
postoperative removal of indwelling catheters should never be undertaken if the patient has been 
recommenced on therapeutic anticoagulation therapy. Additionally, if the insertion is traumatic, the 
restarting of anticoagulant medication postoperatively may need to be delayed due to the risk of 
bleeding, haematoma formation and subsequent nerve damage (Horlocker, 2011). Epidural and spinal: 
In the postoperative period the patient must be monitored closely for any signs of neurological 
dysfunction as prompt interventions may be required (AAGBI, 2013). This observation should be 
taken by qualified, trained staff who are aware of the significance and the action required with any 
abnormal values. Epidural blockades are known to cause hypotension (low blood pressure), however, 
it is important to be mindful that postoperatively, hypotension can occur for various reasons, such as 
myocardial insufficiency, sepsis or dehydration, so these should be considered and excluded (AAGBI, 
2013). Postoperatively, if haemostasis has been achieved, warfarin can usually be recommenced at the 




The increase of individuals living with complex needs and comorbidities means that the NHS is 
treating more and more surgical patients (National Patient Safety Agency, 2008; Holt, 2012; Dhatariya, 
et al., 2016; Keeling, Tait and Watson, 2016).  Patients who are undergoing continuous anticoagulant 
therapy are more at risk of several conditions, such as severe headaches, stomach pain and vision 
changes, but bleeding is a frequent issue that these individuals face. It is a responsibility of every 
healthcare professional to ensure that all patients are as safe as possible, so when these patients require 
surgical intervention, it is important that altered management strategies and associated risks are a part 
of healthcare education to ensure continued safety for these patients. With approximately eight million 
surgical interventions carried out every year by the NHS, the continued awareness of conditions and 
diseases, such as cardiovascular disorders (people with atrial fibrillation and mechanical prosthetic 
heart valves), that impact the care of the surgical patient is an important part of becoming a well-
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Figure 1: Example of VTE Risk Assessment 
BNJ: Please seek permission to use this table or use any VTE risk assessment that you may 




















Figure 2: Comparisons between UFH and LMWH 
 













• Increased half-life with increased 
concentration
• Non-specific protein binding
• <50% bioavailability 
(subcutaneously)
• Hepatic and renal elimination
• Risk of heparin-induced 
thrombocytopenia
• Risk of osteoporosis with 
prolonged treatment
Low molecular weight heparin
• More predictable dose response 
and stable half-life
• Lower non-specific protein 
binding
• >90% bioavailabilty 
(subcutaneously)
• Renal elimination
• Lower risk of heparin-induced  
thrombocytopenia
• Lower risk of osteoporosis
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Figure3: Risk of thromboembolism and bridging anticoagulants  
Risk Level 
*Relevant comorbidities include previous surgery, 
trauma, immobility, malignancy, cancer therapy, 
older age, pregnancy, medical illness, cardiac or 
pulmonary failure, obesity and smoking 
Patient Stratification 
Low Minor surgery. Patients under 40 years old with no 
associated comorbidities. 
No bridging therapy required.  
Moderate Minor surgery. Patients have some relevant 
comorbidities OR are ages 40-60  years old without 
the associated risk factors.  
Bridging therapy conducted on an individual basis 
depending on the type and bleeding risk of the 
surgery. 
High • Major Surgery.  
• Patients over 60 years old.  
• Patients 40-60 years old with relevant 
comorbidities. 
Bridging therapy should be considered. 
Highest Major Surgery. Patients over 60 years old with 
multiple associated comorbidities.  
Bridging therapy should be considered and warfarin 
should be stopped 5 days before the surgery. 
Treatment dose of LMWH on days 4, 3 and 2 before 
surgery (if INR >2.5 give vitamin K). The day before 
surgery half treatment dose of LMWH. On the day 
of surgery, LMWH stopped and INR checked. 
Postoperatively LMWH administered until Warfarin 
commenced. 












Figure 4 – Coagulation Cascade 








• Page 2, line 7, this last statement regarding categories of anticoagulant therapy requires 
further clarification with the use of examples – further clarification and examples added 
• Page 2, paragraph 2, line 3 - coagulation factors also give names with the numbers as these 
are perhaps more familiar to practitioners. Put the number of the factor in brackets – details 
added 
• Page 2, paragraph 2, line 6 - clarification required regarding half-life and pharmacological 
interactions of warfarin follow up with examples – further detail added 
• Page 2, paragraph 3, line 2 - clarify in relation to cascade – detail added and image of cascade 
added 
• Page 3 - subtitle - INR - in full and then put abbreviation in brackets - amended 
• Page 3, 1st sentence - reword to include INR for flow i.e. don't begin with 'This is' following 
any title, apply to any other similar areas in text - amended 
• Page 3, section on INR - need to link clearly into the cascade i.e. at which point each of these 
events happened for both warfarin and vit. K – detail added and linked to cascade 
• Page 3 - subtitle - Thromboembolism Risk - line 4, last word change from 'to' to 'of' - 
amended 
• Page 3 - subtitle - Thromboembolism Risk - line 7 - clarity in relation to anaesthesia and 
surgery - amended 
• Page 4 - line 3 and 4 - this sentence requires clarification as strokes are caused by bleeding 
however you need to clarify fatalities from bleeding as either trauma or post surgery 
complication – sentence amended  
• Page 4, last sentence, numbers under 10 should be in words i.e. five, apply this rule to all 
numbers in text. Also this sentence should include information regarding INR and when last 
tested – number amended and additional information added 
• Page 5 - subtitle Bridging Therapy - you need to define bridging therapy at the beginning of 
this section not the end for reader understanding – section amended 
• Page 5 - subtitle - Neuraxial and peripheral nerve blocks - line 6 - be specific regarding 'most 
optimum' – section amended 
• Page5/6 - last two sentences regarding monitoring of spinal, epidurals this requires greater 




• Conclusion - line 3 - rewording here what do you mean by several conditions? – section 
amended 
• Conclusion - line 10 - insert perioperative practitioner and this covers all who work in the 
perioperative environment. Also at the end of this line you state 'conditions' this requires 
clarity - amended 
• Reference list - last reference incomplete - amended 
 
